A Phase I Study of the Treatment of Recurrent Malignant Glioma with CAN-3110 (AKA rQNestin34.5v.2), a Genetically Engineered HSV-1 Virus
Demographics (3)
- Age - Patient age at time of trial enrollment in years. (phv00531095.v2.p1)
- Gender - Patient biological gender. (phv00531096.v2.p1)
- SEX - Biological sex (phv00531088.v2.p1)
Disease Events (1)
- Deceased - Flag to indicate if patient is deceased (1) or alive (0) at time of last follow up. (phv00531111.v2.p1)
Other (45)
- ANALYTE_TYPE - Analyte Type (phv00531131.v2.p1)
- BODY_SITE - Body site where sample was collected (phv00531130.v2.p1)
- Cohort - Cohort of the clinical trial in which the patient was enrolled. (phv00531092.v2.p1)
- COLLECTION_TIMEPOINT - Timepoint at which tissue sample was collected, counted as days after CAN-3110 injection. Note that "28retreat" samples index this value based on the day of patient 28's second CAN-3110 injection, which occurred 259 days after the first CAN-3110 injection. (phv00531134.v2.p1)
- CONSENT - Consent group as determined by DAC (phv00531087.v2.p1)
- Grade - Tumor grade. (phv00531098.v2.p1)
- HISTOLOGICAL_TYPE - Cell or tissue type or subtype of sample (phv00531133.v2.p1)
- IDH - Tumor IDH mutation status. (phv00531099.v2.p1)
- IS_TUMOR - Tumor status (phv00531132.v2.p1)
- KPS - Karnofsky performance status score at the time of trial enrollment. (phv00531097.v2.p1)
- MGMT - Tumor MGMT methylation status. (phv00531100.v2.p1)
- Pathological_Diagnosis_at_time_of_injection - Pathological diagnosis at time of CAN3110 injection as defined by 2021 classifications. (phv00531101.v2.p1)
- Pathology_CD20_post_n_per_mm3 - Number of CD20+ cells observed per mm^3 in the post-CAN3110 pathology sample. (phv00531123.v2.p1)
- Pathology_CD20_post_Perinecrotic_n_per_mm3 - Number of CD20+ cells observed in the perinecrotic region per mm^3 in the post-CAN3110 pathology sample. (phv00531126.v2.p1)
- Pathology_CD20_pre_n_per_mm3 - Number of CD20+ cells observed per mm^3 in the pre-CAN3110 pathology sample. (phv00531120.v2.p1)
- Pathology_CD4_post_n_per_mm3 - Number of CD4+ cells observed per mm^3 in the post-CAN3110 pathology sample. (phv00531122.v2.p1)
- Pathology_CD4_post_Perinecrotic_n_per_mm3 - Number of CD4+ cells observed in the perinecrotic region per mm^3 in the post-CAN3110 pathology sample. (phv00531125.v2.p1)
- Pathology_CD4_pre_n_per_mm3 - Number of CD4+ cells observed per mm^3 in the pre-CAN3110 pathology sample. (phv00531119.v2.p1)
- Pathology_CD8_post_n_per_mm3 - Number of CD8+ cells observed per mm^3 in the post-CAN3110 pathology sample. (phv00531121.v2.p1)
- Pathology_CD8_post_Perinecrotic_n_per_mm3 - Number of CD8+ cells observed in the perinecrotic region per mm^3 in the post-CAN3110 pathology sample. (phv00531124.v2.p1)
- Pathology_CD8_pre_n_per_mm3 - Number of CD8+ cells observed per mm^3 in the pre-CAN3110 pathology sample. (phv00531118.v2.p1)
- Pathology_HSV_Post_CAN3110_Day_Positive - The day (post CAN3110 injection) on which tissue was collected which tested HSV positive. If positive testing was obtained on multiple days, the latest positive timepoint is recorded. If all samples were negative, the earliest negative timepoint is recorded. (phv00531128.v2.p1)
- Pathology_HSV_Post_CAN3110_Detail - HSV1 IHC staining for post-treatment tumor samples. "Positive", "Multifocal", "Focal", or "Weak" if patient had any post-treatment tumor samples with those staining calls, with same order of precedence. "Negative" if patient had one or more post-treatment samples tested for HSV via IHC and all results were negative. NA if no post-treatment samples were tested for HSV staining via IHC for that patient. (phv00531127.v2.p1)
- Pathology_Post_Sample_Days_post_CAN3110 - Timepoint at which post-CAN3110 pathology sample was collected as measured in days post-CAN3110 injection. When multiple timepoints were available, the timepoint with the highest number of CD4 + CD8 cells was selected. (phv00531116.v2.p1)
- Pathology_Pre_Sample_Days_post_CAN3110 - Timepoint at which pre-CAN3110 pathology sample was collected as measured in days post-CAN3110 injection. (phv00531114.v2.p1)
- Pathology_Tissue_Source_post - Source of post-treatment tumor tissue for pathology data. (phv00531117.v2.p1)
- Pathology_Tissue_Source_pre - Source of pre-treatment tumor tissue for pathology data. (phv00531115.v2.p1)
- PFU_CAN3110 - Dose of CAN3110 (aka rQNestin) virus used to treat this patient in plaque-forming units (PFU). (phv00531093.v2.p1)
- Post_CAN3110_HSV1_Blood_PCR - Detectability of HSV1 in blood via PCR after CAN3110 treatment. (phv00531104.v2.p1)
- Post_CAN3110_HSV1_Serology_Status - HSV1 serology status after treatment with CAN3110. (phv00531103.v2.p1)
- Post_CAN3110_HSV2_Blood_PCR - Detectability of HSV2 in blood via PCR after CAN3110 treatment. (phv00531107.v2.p1)
- Post_CAN3110_HSV2_Serology_Status - HSV2 serology status after treatment with CAN3110. (phv00531106.v2.p1)
- Post_CAN3110_PFS_Days - Number of days from CAN3110 treatment to patient disease progression or death. This day was defined as earliest date of: 1) Death; 2) First new treatment following CAN-3110; or 3) First MRI Progression after CAN-3110. Note that only MRI's taken at least 14 days post CAN-3110 were considered. Also note that the following therapies were excluded from consideration when determining first new treatment: Dexamethasone, Wound Exploration, CSF Wound Drain, Bevacizumab, Cranial Wound Washout, and Biopsy. Note that PFS dates for cohort B patient are preliminary. (phv00531110.v2.p1)
- Post_CAN3110_Survival_Days - Number of days patient survived from time of CAN3110 treatment to death or last follow up. (phv00531109.v2.p1)
- Pre_CAN3110_HSV1_Serology_Status - HSV1 serology status prior to treatment with CAN3110 (which is a modified HSV1). (phv00531102.v2.p1)
- Pre_CAN3110_HSV2_Serology_Status - HSV2 serology status prior to treatment with CAN3110 (which is a modified HSV2). (phv00531105.v2.p1)
- Reason_for_Death - Flag indicating if patient's death was cancer or non-cancer related. (phv00531112.v2.p1)
- Recurrence_number_at_CAN3110_Injection - Number of tumor recurrences for patient prior to enrollment in CAN3110 trial. (phv00531094.v2.p1)
- SAMPLE_ID - Sample ID (phv00531129.v2.p1)
- SAMPLE_ID - Sample ID (phv00531090.v2.p1)
- SUBJECT_ID - Subject ID (phv00531091.v2.p1)
- SUBJECT_ID - Subject ID (phv00531086.v2.p1)
- SUBJECT_ID - Subject ID (phv00531089.v2.p1)
- Time_From_Diagnosis_to_CAN3110_Days - Number of days from initial tumor diagnosis to CAN3110 treatment. (phv00531108.v2.p1)
- Tumor_Volume_at_CAN3110_Injection_mm3 - Volume of patient's tumor at time of CAN3110 injection in mm^3. (phv00531113.v2.p1)